Selinexor

Drug Profile

Selinexor

Alternative Names: CRM1-nuclear-export-inhibitor; KPT-330; KPT-330-003

Latest Information Update: 22 May 2017

Price : $50

At a glance

  • Originator Karyopharm Therapeutics
  • Developer Cardiff University; Dana-Farber Cancer Institute; Erasmus MC; H. Lee Moffitt Cancer Center and Research Institute; Karyopharm Therapeutics; Lymphoma Academic Research Organisation; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); National University Hospital (Singapore); Rigshospitalet; Sheba Medical Center; St. Jude Childrens Research Hospital; The Ohio State University Comprehensive Cancer Center; University of Chicago; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Weill Cornell Medical College
  • Class Acrylamides; Antineoplastics; Hydrazines; Pyrazines; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors; Nuclear export inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma; Acute myeloid leukaemia; Chronic lymphocytic leukaemia; Multiple myeloma; Soft tissue sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Multiple myeloma
  • Phase II/III Liposarcoma
  • Phase II Acute myeloid leukaemia; Breast cancer; Cervical cancer; Cutaneous T cell lymphoma; Diffuse large B cell lymphoma; Endometrial cancer; Glioblastoma; Myelodysplastic syndromes; Neuroendocrine tumours; Ovarian cancer; Peripheral T-cell lymphoma; Prostate cancer; Small cell lung cancer; Squamous cell cancer; Thymoma
  • Phase I/II Chronic myelomonocytic leukaemia; Soft tissue sarcoma
  • Phase I B cell lymphoma; Chronic lymphocytic leukaemia; Colorectal cancer; Diabetic foot ulcer; Gastric cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Oesophageal cancer; Osteosarcoma; Rectal cancer; Solid tumours
  • Preclinical Myelofibrosis; Non-small cell lung cancer

Most Recent Events

  • 12 May 2017 Barbara Ann Karmanos Cancer Institute and National Cancer Institute plan a phase I/II trial for Non-Hodgkin's lymphoma (Combination therapy, Late-stage disease, Relapsed, Refractory metastatic disease) (NCT03147885)
  • 09 May 2017 Karyopharm Therapeutics re-initiates enrolment in a phase II trial in Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO) (NCT02228525)
  • 06 May 2017 Additional safety data from the phase II KING trial in Glioblastoma released by Karyopharma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top